Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRX100 Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors
NCT04282044Phase 1Recruiting
- Sponsor
- BioEclipse Therapeutics
- Start
- Jan 2021
- Primary completion
- Aug 2025
- Modality
- Prophylactic Vaccines, Oncolytic Viruses, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CRX100 in triple-negative breast cancer (TNBC), colorectal cancer (CRC), hepatocellular carcinoma (HCC) and 5 more, sponsored by BioEclipse Therapeutics. Primary endpoints: Frequency of treatment-emergent Adverse Events and Dose Limiting Toxicities at 28 days and Maximum Tolerated Dose, Maximum Feasible Dose or Optimal Biological Dose at 28 days. Started Jan 2021; status: recruiting.
02
Drugs
CRX100
03
Conditions
triple-negative breast cancer (TNBC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)osteosarcoma (OS)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04282044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282044.